Login / Signup

Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation.

Philipp ErnstJenny RinkeGeorg-Nikolaus FrankeFrank DickerTorsten HaferlachThomas ErnstAndreas Hochhaus
Published in: Leukemia (2024)
Keyphrases
  • chronic myeloid leukemia
  • tyrosine kinase
  • disease activity
  • acute lymphoblastic leukemia
  • systemic lupus erythematosus
  • mesenchymal stem cells
  • cell therapy
  • single cell